Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more

Recent & Breaking News (NDAQ:NVCR)

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  May 24, 2017

Research Reports Initiation on Medical Equipment Stocks -- Masimo, NovoCure, Nxstage Medical, and Varex Imaging

PR Newswire May 22, 2017

Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

Business Wire May 15, 2017

Martin J. Madden Joins Novocure Board of Directors

Business Wire May 11, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients

Business Wire May 8, 2017

Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas

Business Wire May 4, 2017

Novocure to Present at Three Upcoming Investor Conferences in May

Business Wire May 1, 2017

Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting

Business Wire May 1, 2017

Novocure Reports First Quarter 2017 Financial Results and Provides Company Update

Business Wire April 27, 2017

CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence

Business Wire April 17, 2017

Mid-Afternoon Market Update: NovoCure Surges After Two-Year Survival Rate Increases For GBM Patients; Diffusion Pharma Shares Slide

Benzinga.com  April 3, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  April 3, 2017

Mid-Day Market Update: Dow Drops Over 100 Points; DryShips Shares Plummet

Benzinga.com  April 3, 2017

22 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  April 3, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients

Business Wire April 2, 2017

Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer

Business Wire March 31, 2017

Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer

Business Wire March 31, 2017

Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma

Business Wire March 31, 2017

Novocure to Report First Quarter 2017 Financial Results

Business Wire March 28, 2017

Novocure to Present at the 16th Annual Needham & Company Healthcare Conference

Business Wire March 28, 2017